Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Tempest Therapeutics, Inc. (TPST)

Tempest Therapeutics appoints John Frederick, former Skillsoft CFO, to board

Neutral Impact 2 of 5 leadership Written later

Tempest Therapeutics appointed John Frederick as a Class III director effective October 13, 2026. Frederick previously served as Chief Financial Officer of Skillsoft Corp. from May 2025 to September 2026, and the filing describes his board term as running until the 2027 annual meeting.

Key points

  • Board appointment effective October 13, 2026; term runs until the Company's 2027 annual meeting of stockholders
  • Frederick to receive an initial option award to purchase 25,000 shares of common stock under the 2023 Equity Incentive Plan
  • Frederick was CFO of Skillsoft Corp. (NYSE: SKIL) from May 2025 to September 2026
  • Press release announcing the appointment issued October 14, 2026 and furnished as Exhibit 99.1

The filing

CompanyTempest Therapeutics, Inc. (TPST)
Form8-K, current report
Filed with the SECOct 19, 2026, 4:05 PM ET
Accession number0001213900-26-110669

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 19, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.